New FDA Rules Clarify Generic Drug Equivalence Tests
Published Date: 5/29/2026
Notice
Summary
The FDA just released final guidance to help drug companies prove their generic drugs work just like the original ones by using bioequivalence studies. This affects anyone submitting or updating abbreviated new drug applications (ANDAs) and aims to make the approval process clearer and smoother. Companies should review these new rules now to avoid delays and extra costs when getting their generics to market.
Analyzed Economic Effects
5 provisions identified: 5 benefits, 0 costs, 0 mixed.
Final BE Guidance for ANDA Applicants
The FDA issued final guidance titled "Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA" on May 29, 2026. The guidance gives recommendations to applicants planning to include bioequivalence (BE) information in abbreviated new drug applications (ANDAs), ANDA amendments, and ANDA supplements and is intended to make the approval process clearer and smoother so companies should review it now to avoid delays and extra costs when getting generics to market.
Key Updates from Draft to Final
The final guidance includes updates to align recommendations with the M13A guidance issued October 31, 2024, clarifications about study population and study design, updates to in vitro dissolution testing information, and removal of certain statistical-analysis appendices (those appendices were incorporated into the concurrently issued guidance "Statistical Approaches to Establishing Bioequivalence").
Which Products the Guidance Covers
The guidance applies to immediate-release and modified-release oral dosage forms and to non-oral drug products where systemic exposure measures can establish bioequivalence, for example transdermal delivery systems and certain rectal and nasal drug products. It also applies when applicants plan BE studies during the postapproval period for changes to a drug product approved under an ANDA.
Guidance Is Non-Binding; Alternatives Allowed
The guidance represents FDA's current thinking but does not establish any rights and is not binding on FDA or the public; applicants may use an alternative approach if it satisfies applicable statutes and regulations. FDA finalized this guidance consistent with its good guidance practices (21 CFR 10.115).
No New Information Collection Burden
The guidance itself contains no new collection of information. It refers to previously approved information collections under several OMB control numbers (for example, OMB control numbers 0910-0130, 0910-0572, 0910-0014, 0910-0291, 0910-0001, 0910-0191, 0910-0727, and 0910-0119) that remain subject to the Paperwork Reduction Act of 1995 review.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10734 — Content of Human Factors Information in Medical Device Marketing Submissions; Guidance for Industry and Food and Drug Administration Staff; Availability
The FDA just released new guidance to help medical device makers include the right human factors info in their marketing submissions. This makes the review process faster and clearer for everyone involved. If you make or review medical devices, get ready to follow these updated steps starting now—saving time and possibly money!
2026-10675 — Medical Devices; Neurological Devices; Classification of the Transcutaneous Electrical Nerve Stimulator To Treat Fibromyalgia Symptoms
The FDA is officially classifying the transcutaneous electrical nerve stimulator for fibromyalgia as a Class II device, meaning it’s safe and effective with some special rules. This change helps patients get easier access to this innovative treatment by cutting down red tape. The new classification is effective May 29, 2026, and could speed up device availability without extra costs for makers or users.
2026-10674 — Advisory Committee; Psychopharmacologic Drugs Advisory Committee; Renewal
The FDA is renewing the Psychopharmacologic Drugs Advisory Committee for two more years, keeping it active until June 4, 2028. This committee helps make sure psychiatric drugs are safe and effective, affecting drug makers, doctors, and patients. No new costs or big changes, just a smooth continuation of expert advice to keep mental health treatments on track.
2026-10614 — Color Additive Petition from Environmental Defense Fund, et al.; Request To Amend the Color Additive Regulations To Remove the Solvents Ethylene Dichloride, Methylene Chloride, and Trichloroethylene; Reopening of the Comment Period
The FDA is reopening the comment period on a petition from the Environmental Defense Fund and others to remove three harmful solvents—ethylene dichloride, methylene chloride, and trichloroethylene—from color additive rules. This change affects companies using these solvents in color additives and aims to make products safer. Comments are open until June 29, 2026, giving everyone a chance to share new info before any final decisions.
2026-10615 — Food Additive Petition From Environmental Defense Fund, et al.; Request To Amend the Food Additive Regulations To Remove the Solvents Benzene, Ethylene Dichloride, Methylene Chloride, and Trichloroethylene; Reopening of the Comment Period
The FDA is reopening the comment period on a petition from the Environmental Defense Fund and others to remove four harmful solvents—benzene, ethylene dichloride, methylene chloride, and trichloroethylene—from food additive rules. This change affects food makers who use these solvents and aims to make our food safer. Comments are open until June 29, 2026, giving everyone a chance to share new info before any costly changes happen.
2026-10603 — Challenges and Solutions in Lot-Level Food Traceability; Public Meeting and Request for Comments
The FDA is hosting a virtual meeting on June 15, 2026, to talk about how to better track food by its lot number, making food safer and easier to trace. This affects food producers, sellers, and anyone involved in food safety, with a chance to suggest flexible ways to follow the rules. Comments on the ideas are open until July 15, 2026, so get involved and help shape the future of food tracking!
Previous / Next Documents
Previous: 2026-10702 — State of Indiana: NRC Staff Assessment of a Proposed Agreement Between the Nuclear Regulatory Commission and the State of Indiana
The Nuclear Regulatory Commission (NRC) is teaming up with Indiana to let the state take charge of some nuclear safety rules. This means Indiana will handle certain nuclear materials oversight, helping protect public health while keeping things running smoothly. People have until June 15, 2026, to share their thoughts before the agreement moves forward—no big costs or delays expected!
Next: 2026-10704 — Extension of Lebanon Designation for Temporary Protected Status
Lebanon’s Temporary Protected Status (TPS) has been extended for six more months, from May 28 to November 27, 2026. This means Lebanese TPS holders can keep living and working in the U.S. without worry while the government reviews conditions back home. The extension happened automatically because recent events in Lebanon delayed the usual review process.